Magdalena Zielonka

Magdalena Zielonka

Auto-generated profile, based on publicly available information

Magdalena Zielonka

Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2025 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
GAGiulia Albertini
Giulia Albertini
MZMagdalena Zielonka
Magdalena Zielonka
MCMarie-Lynn Cuypers
Marie-Lynn Cuypers
ASAn Snellinx
An Snellinx
CXCiana Xu
Ciana Xu
BSBart De Strooper
Bart De Strooper
Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. Here we demonstrate that Lecanemab, a leading anti-β-amyloid (Aβ) antibody, mediates amyloid clearance by activating microglial effector functions. Using a human microglia xenograft mouse model, we show that Lecanemab significantly reduces Aβ pathology and associated neuritic damage, while neither fragment crystallizable (Fc)-silenced Lecanemab nor microglia deficiency elicits this effect despite intact plaque binding. Single-cell RNA sequencing and spatial transcriptomic analyses reveal that Lecanemab induces a focused transcriptional program that enhances phagocytosis, lysosomal degradation, metabolic reprogramming, interferon γ genes and antigen presentation. Finally, we identify SPP1 /osteopontin as a major factor induced by Lecanemab treatment and demonstrate its role in promoting Aβ clearance. These findings highlight that effective amyloid removal depends on the engagement of microglia through the Fc fragment, providing critical insights for optimizing anti-amyloid therapies in Alzheimer’s disease.

4 June 2026 in Nature Medicine
Verified
Journal Article
Open access
ALAshley Lu
Ashley Lu
WCWei-Ting Chen
Wei-Ting Chen
MDMaria Dalby
Maria Dalby
DGDiego Sainz Garcia
Diego Sainz Garcia
MVMarisa Vanheusden
Marisa Vanheusden
BSBart De Strooper
Bart De Strooper
Alzheimer’s disease (AD) is not an inevitable outcome of pathology but a dynamic process shaped by how brain cells respond to amyloid-β (Aβ) and tau. To disentangle these responses, we combined spatial transcriptomics and single-nucleus RNA sequencing of the superior frontal cortex from octogenarians living with or without dementia and from cognitively intact centenarians with comparable Aβ accumulation. We identified six distinct tissue domains representing a spatial pathological continuum of AD, with a key inflection point marked by a shift from Aβ-associated inflammatory changes to tau-associated cellular programs. This transition was accompanied by a change in microglial states, from early inflammatory to late antigen-presenting phenotypes, termed early and late plaque-induced gene (PIG) programs. Resilient individuals showed distinct pathological patterns: octogenarians without dementia lacked late PIGs, whereas centenarians showed late PIG activation that was uncoupled from tau accumulation. Together, these findings highlight divergent resilience-associated mechanisms in human aging and position microglial state transitions at the Aβ−tau interface as candidate points of resilience with potential therapeutic relevance.

1 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAnna Mallach
Anna Mallach
MZMagdalena Zielonka
Magdalena Zielonka
VLVeerle van Lieshout
Veerle van Lieshout
YAYanru An
Yanru An
JKJia Hui Khoo
Jia Hui Khoo
BSBart De Strooper
Bart De Strooper
The amyloid plaque cell niche is a pivotal hallmark of Alzheimer’s disease (AD). Where early spatial transcriptomics (ST) technologies have provided valuable information on transcriptomic alterations in the small tissue domains overlaying with amyloid plaques, they lacked cellular resolution. Here we compare two novel high-resolution ST platforms, CosMx and Stereo-seq, in their ability to characterize the cellular response in the amyloid plaque niche in an AD mouse model. Combining the results from both techniques empowered us to survey the highly variable microglial-astrocytic response across the amyloid plaque micro-environment and provided a first insight into how these responses could relate to neuronal transcriptomic alterations. This pilot study demonstrates the great potential of high-resolution ST, while simultaneously highlighting limitations that, when addressed, will unleash the full power of these techniques to map the progression of molecular and cellular changes in the brains of AD patients.

17 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSamuel L. Boulger
Samuel L. Boulger
LMLeire Melgosa-Ecenarro
Leire Melgosa-Ecenarro
MZMagdalena Zielonka
Magdalena Zielonka
KPKjara S. Pilch
Kjara S. Pilch
SWSasvi S. Wijesinghe
Sasvi S. Wijesinghe
AMAnna Mallach
Anna Mallach
Cells in the brain have complex structures with extended processes. This complex morphology supports diverse specialized functions in health and disease, and specifically, cell processes appear to be critical for cellular integration and signalling. Here, we developed a new spatial averaging framework to recover and interrogate molecular phenotypes of glial processes in spatial transcriptomics (ST) data. We characterised cell type specific signatures associated with processes of astrocytes and microglia in both mouse and human brain tissue. Astrocytic processes were enriched for transcripts related to neuronal support relative to their soma, while microglial processes preferentially expressed genes linked to specific microglial states. When investigated in tissue from brains with Alzheimer’s Disease (AD) pathology, we found that local amyloid-β pathology was associated with subcellular differences in transcriptomes in both an amyloid-β mouse model and human AD patient tissue. Specifically, astrocytic and microglial processes oriented toward amyloid-β plaques exhibited distinct molecular changes in comparison to processes extending away into plaque free areas, suggesting polarized glial responses to pathology. Our work thus outlines a general method for the selective characterisation of transcriptomics of glial processes in mouse and human ST data and provides evidence for differential transcriptomic responses between the soma and processes of glia in health and disease. Graphical

15 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MZMagdalena Zielonka
Magdalena Zielonka
AMAnna Mallach
Anna Mallach
BSBart De Strooper
Bart De Strooper
MFMark Fiers
Mark Fiers
Identifying the molecular cascade underlying neuronal degeneration in Alzheimer’s disease has been hampered by cellular heterogeneity and the limitations of donor-level classification. By integrating 851,682 cortical layer 2 and 3 excitatory neuron transcriptomes from 557 individuals across four independent snRNA-seq datasets of the human prefrontal cortex, we reconstruct neuronal degeneration as a continuous, stage-resolved transcriptional trajectory. Ordering neurons by collective pathological burden and clinical manifestation reveals that degeneration unfolds asynchronously within individual brains. Neurons in a single brain can simultaneously occupy early, intermediate, and late pathological states, a continuum entirely obscured by conventional approaches. The trajectory captures discrete transcriptional inflection points defining successive stages of vulnerability linked to development of neuropathology. Systematic analysis of the complete human kinome and phosphatome along this trajectory identifies a temporal hierarchy of phosphorylation dysregulation which collectively creates a permissive environment for tau pathology to escalate, defining stage-specific molecular nodes in the degenerative cascade.